CompagOs

🎄✨ We wish all our colleagues, partners, supporters, and bone enthusiasts a joyful holiday season and a New Year filled with innovation and success. ✨🎄 Thank you for being part of our journey as we continue to grow stronger together—just like our 3D bioprinted Bon3OID™ models! 🦴💡 Happy Holidays and a prosperous 2024! 🎉 #MerryChristmas #HappyNewYear #Innovation

🌟 Exciting News! 🌟 We’re extremely happy to share that CompagOs, in collaboration with CSEM and the Université de Fribourg/Universität Freiburg, has received an Innosuisse grant to develop the world’s first semi-automated machine for producing biomechanically loaded in vitro bone models to detect bone metastases from blood samples. 💡 Why this matters Bone metastases affect over 2 million patients annually and are often detected too late with traditional imaging methods. Our Bon3OID™ technology provides earlier insights by identifying biological markers of metastatic bone activity, paving the way for timely interventions and improved patient outcomes. 🔑 Key highlights - Collaboration with leading experts in life sciences, access to an advanced patient sample database, and advanced blood analytic capabilities. - A 24-month project dedicated to automating, scaling, and validating the technology to achieve clinical-grade quality. - Potential for future applications in diagnosing other conditions, such as osteoporosis and rheumatoid arthritis. 🎯 What’s Next The project will leverage CSEM’s expertise to standardize and semi-automate Bon3OID™ in vitro bone model production. Clinical validation will be conducted on patient samples collected from cancer patients treated at the hôpital fribourgeois (HFR) – freiburger spital (HFR) with the support of the Laboratory of Applied Cancer Research at the University of Fribourg, renowned for their expertise in advanced blood analysis. 🌍 Outcome of the project The project aims to develop a semi-automated, standardized production process, enabling a clinical study to collect the data needed for market entry. We’re immensely grateful for Innosuisse’s and our partners' support and excited to take this important step in advancing bone health! 📌 Read and download the full press release here: https://lnkd.in/eHW5FMhU Gian Nutal S. Robert Baumann Chris Steffi Barna Gal, MD Gilles Weder Alessandra Curioni Fontecedro #Innovation #BoneHealth #3DInVitroBoneModels #CancerDiagnostics #3DBioprinting #LifeSciences #Healthcare

🚀 Got a minute? ⏱️ The survey is still live, and your feedback would mean the 🌍 to us! 🙌 Please take a moment to share your thoughts!💡

🔍 Check out this short video and discover in just one minute how we're redefining bone health! Thx Supertrends for sharing💪

🦴 How Do You Get Information About a Patient’s Bones From Blood? 🦴Through Bone Biomarkers! Examples like osteocalcin, CTX (C-terminal telopeptide), P1NP (Procollagen Type I N Propeptide), and ALP (Alkaline Phosphatase) are powerful tools in bone health research and clinical practice. However, they come with limitations that impact their effectiveness in diagnosing and monitoring bone diseases. 🤔 What do you think are the biggest limitations of current bone biomarkers? 📊 Your perspective matters! Join the conversation and vote 🔽 below to help uncover insights that can drive innovation and potentially lead to better, more effective bone biomarkers. Please also share this survey with researchers or clinicians in the bone field. 💬 Have more to share? You can send us a message or leave a comment if there’s more you’d like to share beyond the survey. We’d love to hear from you! #BoneBiomarkers #Diagnostics #BoneHealth #MedicalResearch #Innovation

🔎 How do monocytes shape bone remodeling—and why should they be part of advanced 3D in vitro systems? Monocytes are the unsung heroes of bone health, playing a pivotal role in osteoclast formation. When they differentiate into osteoclasts, they drive bone resorption, balancing the constant remodeling process necessary for bone maintenance and repair. But why include osteoclasts in 3D in vitro systems? 🦴 Because bone resorption matters. To fully understand bone diseases like osteoporosis, rheumatoid arthritis, or bone metastases, it's essential to capture the interplay between bone-forming cells (osteoblasts) and bone-resorbing cells (osteoclasts). That’s where our Bon3OID™-OC model comes in. This cutting-edge system incorporates monocytes, which differentiate into osteoclasts, enabling a dynamic and realistic study of bone remodeling. It allows for longitudinal drug assessment, quantifying the amount of mineral resorbed by osteoclasts over time. For research focusing solely on osteoblast activity, we also offer our flagship Bon3OID™ model—without monocytes—providing flexibility tailored to your study's needs. 🖼️ Image Right: Bon3OID™-OC with monocytes—osteoclast differentiation and bone resorption. 🖼️ Image Left: Bon3OID™ without monocytes—osteoblast activity in focus. If you’re a researcher tackling bone health challenges, we’d love to help! 💡 Reach out for a free consultation on how our models can empower your next project. #InVitroBoneModel #BoneResearch #Osteoclasts #Osteoblasts

🚀 We’re excited to participate in ETH Industry Day on 21.11! As a company focused on advancing bone health, we are pioneering solutions to understand, diagnose, and treat bone conditions using our Bon3OID™ in vitro model technology. What does that mean? 🦴 Understand: We offer comprehensive research services for the life science industry. 🔬 Diagnose: We are developing a blood-based assay for the early detection of bone metastases. 💡 Treat: We envision our technology supporting bone regeneration in the future. We’re looking to connect with customers who want to use our services, partners to co-develop diagnostic and therapeutic solutions, and investors, who want to join us on this journey with their knowledge and financial support. Our team, Gian Nutal S., Chris Steffi and Robert Baumann will be on-site and ready to engage! Visit them at booth Nr. 101 or find them around the venue. Feel free to reach out directly to arrange a meeting in advance. We look forward to meeting you! 🔗 For more details, visit: https://lnkd.in/dPEhQPS ETH Zürich ETH Zurich Industry Relations Open-i #Innovation #BoneHealth #3DOrganotypicBoneModels #3R #PersonalizedMedicine #BoneRegeneration #BoneOncology #BoneMetastasis #Osteoporosis #RheumatoidArthritis #OsteogenesisImperfecta

📢 Check out our latest blog article on personalized medicine and rheumatoid arthritis! Rheumatoid arthritis (RA) is a complex and challenging disease, and finding the right treatment for each patient can be difficult. Our new blog explores how organotypic bone models could be the key to personalized treatment approaches by serving as functional assays. These innovative models replicate the bone microenvironment, helping to predict the most effective therapies for RA patients. 💡 Ready to learn how this approach could improve patient outcomes and reduce healthcare costs? Read the full article here: https://lnkd.in/eUwC-R-K #BoneHealth #OrganotypicBoneModels #RheumatoidArthritis #PersonalizedMedicine #FunctionalPrecisionMedicine

⏳ Just 2 days to go until the NVCB Autumn Meeting in Zeist! We’re excited to be part of this event and can't wait to meet you. Make sure to stop by our booth or find our Co-founder, Gian Nutal S., around the venue to discuss 🦴 bone health, 3D bone cell cultures, and how our mineralized Bon3OID™ in vitro models can support your research. 🚨 Also check out Gian's presentation on Wednesday, 06.11 during Session I! Feel free to reach out directly to arrange a meeting with him ahead of time. 🔗 Last-minute details here: https://lnkd.in/erQrszMY Looking forward to some inspiring conversations and connections! 🙌 #BoneHealth #OrganotypicBoneModels #BoneRegeneration #BoneMetastases #RheumatoidArthritis #Osteoporosis #Osteomyelitis #OsteogenesisImperfecta #Osteosarcoma

📅 Next week, we're heading to Zeist for the NVCB Autumn Meeting! Meet our Co-founder, Gian Nutal S., at our booth or around the venue. Gian is excited to chat about 🦴 bone health, 3D cell cultures in the bone domain, and how our mineralized Bon3OID™ models can support your upcoming projects. ✨ Don’t miss Gian’s presentation on Wednesday, 06.11 during Session I! Feel free to reach out directly to arrange a meeting with him ahead of time. 👉 For more details, visit: https://lnkd.in/erQrszMY We look forward to connecting with fellow bone enthusiasts! 🤝 #BoneHealth #OrganotypicBoneModels #BoneRegeneration #BoneMetastases #RheumatoidArthritis #Osteoporosis #Osteomyelitis #OsteogenesisImperfecta #Osteosarcoma